Translations:Insulin/31/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
FuzzyBot (talk | contribs)
Importing a new version from external source
Tags: Mobile edit Mobile web edit
 
(No difference)

Latest revision as of 16:33, 18 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Insulin)
The description of first phase release is as follows:
* Glucose enters the β-cells through the [[glucose transporters]], [[Glucose transporter|GLUT 2]]. At low blood sugar levels little glucose enters the β-cells; at high blood glucose concentrations large quantities of glucose enter these cells.
* The glucose that enters the β-cell is phosphorylated to [[glucose-6-phosphate]] (G-6-P) by [[glucokinase]] ([[Hexokinase#Types of mammalian hexokinase|hexokinase IV]]) which is not inhibited by G-6-P in the way that the hexokinases in other tissues (hexokinase I – III) are affected by this product. This means that the intracellular G-6-P concentration remains proportional to the blood sugar concentration.
* Glucose-6-phosphate enters [[Glycolysis|glycolytic pathway]] and then, via the [[pyruvate dehydrogenase]] reaction, into the [[Krebs cycle]], where multiple, high-energy [[adenosine triphosphate|ATP]] molecules are produced by the oxidation of [[acetyl CoA]] (the Krebs cycle substrate), leading to a rise in the ATP:ADP ratio within the cell.
* An increased intracellular ATP:ADP ratio closes the ATP-sensitive SUR1/[[Kir6.2]] [[potassium channel]] (see [[sulfonylurea receptor]]). This prevents potassium ions (K<sup>+</sup>) from leaving the cell by facilitated diffusion, leading to a buildup of intracellular potassium ions. As a result, the inside of the cell becomes less negative with respect to the outside, leading to the depolarization of the cell surface membrane.
* Upon [[depolarization]], voltage-gated [[calcium channels|calcium ion (Ca<sup>2+</sup>) channels]] open, allowing calcium ions to move into the cell by facilitated diffusion.
* The cytosolic calcium ion concentration can also be increased by calcium release from intracellular stores via activation of ryanodine receptors.
* The calcium ion concentration in the cytosol of the beta cells can also, or additionally, be increased through the activation of [[phospholipase|phospholipase C]] resulting from the binding of an extracellular [[ligand]] (hormone or neurotransmitter) to a [[G protein]]-coupled membrane receptor. Phospholipase C cleaves the membrane phospholipid, [[phosphatidyl inositol 4,5-bisphosphate]], into [[inositol 1,4,5-trisphosphate]] and [[diglyceride|diacylglycerol]]. Inositol 1,4,5-trisphosphate (IP3) then binds to receptor proteins in the plasma membrane of the [[endoplasmic reticulum]] (ER). This allows the release of Ca<sup>2+</sup> ions from the ER via IP3-gated channels, which raises the cytosolic concentration of calcium ions independently of the effects of a high blood glucose concentration. [[Parasympathetic nervous system|Parasympathetic]] stimulation of the pancreatic islets operates via this pathway to increase insulin secretion into the blood.
* The significantly increased amount of calcium ions in the cells' cytoplasm causes the release into the blood of previously synthesized insulin, which has been stored in intracellular [[secretion|secretory]] [[vesicle (biology)|vesicles]].

The description of first phase release is as follows:

  • Glucose enters the β-cells through the glucose transporters, GLUT 2. At low blood sugar levels little glucose enters the β-cells; at high blood glucose concentrations large quantities of glucose enter these cells.
  • The glucose that enters the β-cell is phosphorylated to glucose-6-phosphate (G-6-P) by glucokinase (hexokinase IV) which is not inhibited by G-6-P in the way that the hexokinases in other tissues (hexokinase I – III) are affected by this product. This means that the intracellular G-6-P concentration remains proportional to the blood sugar concentration.
  • Glucose-6-phosphate enters glycolytic pathway and then, via the pyruvate dehydrogenase reaction, into the Krebs cycle, where multiple, high-energy ATP molecules are produced by the oxidation of acetyl CoA (the Krebs cycle substrate), leading to a rise in the ATP:ADP ratio within the cell.
  • An increased intracellular ATP:ADP ratio closes the ATP-sensitive SUR1/Kir6.2 potassium channel (see sulfonylurea receptor). This prevents potassium ions (K+) from leaving the cell by facilitated diffusion, leading to a buildup of intracellular potassium ions. As a result, the inside of the cell becomes less negative with respect to the outside, leading to the depolarization of the cell surface membrane.
  • Upon depolarization, voltage-gated calcium ion (Ca2+) channels open, allowing calcium ions to move into the cell by facilitated diffusion.
  • The cytosolic calcium ion concentration can also be increased by calcium release from intracellular stores via activation of ryanodine receptors.
  • The calcium ion concentration in the cytosol of the beta cells can also, or additionally, be increased through the activation of phospholipase C resulting from the binding of an extracellular ligand (hormone or neurotransmitter) to a G protein-coupled membrane receptor. Phospholipase C cleaves the membrane phospholipid, phosphatidyl inositol 4,5-bisphosphate, into inositol 1,4,5-trisphosphate and diacylglycerol. Inositol 1,4,5-trisphosphate (IP3) then binds to receptor proteins in the plasma membrane of the endoplasmic reticulum (ER). This allows the release of Ca2+ ions from the ER via IP3-gated channels, which raises the cytosolic concentration of calcium ions independently of the effects of a high blood glucose concentration. Parasympathetic stimulation of the pancreatic islets operates via this pathway to increase insulin secretion into the blood.
  • The significantly increased amount of calcium ions in the cells' cytoplasm causes the release into the blood of previously synthesized insulin, which has been stored in intracellular secretory vesicles.